BioNTech SE (BNTX)

NMS – Цена в реальном времени. Валюта: USD

93.66

+0.32 (0.34%)

При закрытии: May 12, 2026, 4:00 PM EDT

95.18

+1.52 (1.62%)

После закрытия: May 12, 2026, 7:56 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

BioNTech SE (BNTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BioNTech SE (BNTX)

BioNTech Announces New ADS Repurchase Program

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Видео

Пресс-релизы

BioNTech Announces New ADS Repurchase Program

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Search stocks

BioNTech SE (BNTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BioNTech SE (BNTX)

BioNTech Announces New ADS Repurchase Program

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Видео

Пресс-релизы

BioNTech Announces New ADS Repurchase Program

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer